AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01434173 — intervention group
Intervention type: DRUG
Intervention: Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Description: Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
Study NCT02424617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
Study NCT02424617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bemcentinib
Description: Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
Study NCT02424617 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bemcentinib
Description: Bemcentinib is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
Study NCT04440878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Static stretching exercise will be performed under the supervision of a physiotherapist as 30 seconds of stretching and 15 seconds of rest with 10 repetitions, and the individuals will be asked to participate in the exercise actively.
Study NCT04440878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mulligan TSLR technique
Description: Mulligan TSLR will be applied by a physiotherapist in 3 repetitions with the patient in the supine position.
Study NCT05065905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study NCT01844453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
Study NCT00586859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NDO Full-thickness Plicator
Description: The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
Study NCT04680806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser 2780 nm
Description: The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
Study NCT04680806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode laser 940 nm
Description: The depigmentation procedure essentially involves laser ablation of epithelial layer of buccal gingiva containing melanin pigmentation.
Study NCT01655693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 20 mg/m2
Study NCT01655693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 30 mg/m2
Study NCT01655693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care
Study NCT02098330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo biloba & Methylprednisolone
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
Study NCT02098330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo biloba
Description: Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
Study NCT04517149 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-125 IVT Injection
Description: 4D-125 drug product developed for gene therapy, which comprises an AAV capsid variant (4D-R100) carrying a codon-optimized human Retinitis Pigmentosa GTPase Regulator transgene.
Study NCT04517149 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational
Description: Natural History
Study NCT00751361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rheopheresis / double filtration plasmapheresis
Description: Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
Study NCT00741390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BD/33G
Description: BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study NCT00741390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OTM / 33G
Description: OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study NCT04230317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chest CT
Description: Low dose CT taken with three different protocols
Study NCT04230317 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Chest CT
Description: Low dose CT taken with three different protocols
Study NCT03232996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease
Description: All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
Study NCT01454596 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
Description: Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
Study NCT01454596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
Study NCT00741390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OTU/28G
Description: OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
Study NCT00741390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ACC/28G
Description: Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
Study NCT00741390 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OTM/28G
Description: OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
Study NCT01454596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
Study NCT01454596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
Study NCT00620282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Stepwise dose increase, s.c. (under the skin) injection, once daily
Study NCT02412228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years
Study NCT02412228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily
Study NCT02412228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18
Study NCT02703298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-818 capsules
Study NCT03314701 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Intermittent Positive Airway Pressure (BIPAP)
Description: Following endotracheal intubation BIPAP mode will be started with:~* Inspiratory positive airway pressure \[IPAP\] at 20 cmH2O~* Expiratory positive airway pressure \[EPAP\] at 5 cmH2O~* PRESSURE SUPPORT is difference between these two pressures \[IPAP\]- \[EPAP\]~* Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed
Study NCT03314701 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airway Pressure Release Ventilation (APRV)
Description: * high airway pressure (Phigh) will be set at 20 cmH2O~* low airway pressure ( Plow) will be set at 5 cmH2O~* the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~* T high at 4.5-6 seconds~* T low at 0.5 to 0.8 second
Study NCT02838758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
Study NCT02838758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
Study NCT02838758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
Study NCT00488488 — intervention group
Intervention type: DRUG
Intervention: tigecycline
Description: The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study NCT04608565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Remote biomonitoring sensor device
Description: Same as described in arm descriptions. Safety was ensured by getting radiant warmer and multichannel probe examined and services by the biomedical engineering department; calibration certificates were obtained and these were used routinely in care of other neonates. An adverse event reporting and resolution protocol for the wearable sensor devices to capture number and severity of adverse events; individual clinical management and feedback for changes into device design. Adverse events recorded were: dermatitis, infection, thermal injury, radiation injury, device leak/burst and others.
Study NCT00993408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACT-293987 (NS-304)
Study NCT00490269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00490269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Study NCT00376129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: 15 mg i.m. once weekly for 12 weeks
Study NCT00867230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTS
Description: Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
Study NCT02239159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TES(transcutaneous electric stimulation)
Description: Stimulation will be given through electrodes attached to the skin
Study NCT02239159 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: TES(transcutaneous electric stimulation)
Description: Stimulation will be given through electrodes attached to the skin
Study NCT04392817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arabic Articulatory Error Remediation software program
Description: A speech therapy computerized intervention
Study NCT01078441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: Given IV
Study NCT01078441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given subcutaneously.
Study NCT01078441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT01078441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT03523884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program plus Education
Description: Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
Study NCT00620282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
Study NCT00620282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: Tablets, 1 - 4 mg daily
Study NCT02666859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
Study NCT03523884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Program (EP).
Description: An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
Study NCT03523884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Program (EP).
Description: An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
Study NCT02868554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcceleDent Aura
Description: Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
Study NCT02868554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Invisalign therapy
Description: Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
Study NCT02864693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinnex
Description: The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
Study NCT02864693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacifica LP
Description: The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
Study NCT00876577 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
Study NCT00216671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: early initiation of treatment with Risperdal Consta
Description: 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
Study NCT00216671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine initiation of treatment with Risperdal Consta
Description: 25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
Study NCT04410185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditation sessions will take place over 12 weekly sessions of 1.5 hours
Study NCT00133406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
Study NCT04038541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)
Description: Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)
Study NCT04038541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Probiotics (Visbiome®)
Description: Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)
Study NCT03579706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment
Description: The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
Study NCT03579706 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical Health Education Training
Description: The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
Study NCT03390465 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Description: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
Study NCT00133406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
Study NCT03997370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Given IV
Study NCT02103738 — intervention group
Intervention type: OTHER
Intervention: 0.5 mg Ranibizumab intravitreal injections
Description: All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
Study NCT00133406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A
Description: 100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
Study NCT04611256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC
Description: Two intravenous infusion of 1\*10E6 adipose tissue derived-MSCs /kg body weight reach
Study NCT04611256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Conventional treatment that may include analgesic, anti-inflammatory, antibiotic, steroid, antiplatelet, and anticoagulant.